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Background: Therapeutic success of thermal ablation for liver tumors depends on
precise placement of ablation probes and complete tumor destruction with a safety
margin. We investigated factors influencing targeting accuracy and treatment efficacy
of percutaneous stereotactic image-guided microwave ablation (SMWA) for malignant
liver neoplasms.
Materials andmethods : All consecutive patients treated with SMWA for malignant liver
tumors over a 3-year period were analyzed. A computed tomography-based navigation
system was used for ablation probe trajectory planning, stereotactic probe positioning,
and validation of probe positions and ablation zones. Factors potentially influencing
targeting accuracy [target positioning error (TPE)] and treatment efficacy within 6 months
[ablation site recurrence (ASR)] were analyzed in a multivariable regression model,
including challenging lesion locations (liver segments I, VII, and VIII; subphrenic location).
Results: Three hundred one lesions (174 hepatocellular carcinomas, 87 colorectal
liver metastases, 17 neuroendocrine tumors, and 23 others) were targeted in 191
interventions in 153 patients. The median TPE per ablation probe was 2.9 ± 2.3mm
(n = 384). Correction of ablation probe positions by repositioning was necessary in 4 out
of 301 lesions (1%). Factors significantly influencing targeting accuracy were cirrhosis
(R 0.67, CI 0.22–1.12) and targeting trajectory length (R 0.21, CI 0.12–0.29). Factors
significantly influencing early ASR were lesion size >30mm (OR 5.22, CI 2.44–11.19)
and TPE >5mm (OR 2.48, CI 1.06–5.78). Challenging lesion locations had no significant
influence on targeting accuracy or early ASR.
Conclusions: SMWA allows precise and effective treatment of malignant liver tumors
even for lesions in challenging locations, with treatment efficacy depending on targeting
accuracy in our model. Allowing for many tumors to be safely reached, SMWA has
the potential to broaden treatment eligibility for patients with otherwise difficult to
target tumors.
Keywords: liver neoplasms, interventional radiology, ablation techniques, stereotaxic techniques,
computer-assisted therapies
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INTRODUCTION
For patients with malignant liver tumors, thermal ablation
is a locally destructive, low-morbidity, and potentially
curative treatment option, particularly for hepatocellular
carcinoma (HCC) and colorectal liver metastases (CRLM) (1, 2).
Radiofrequency ablation (RFA) or microwave ablation (MWA)
are increasingly used for non-resectable disease (3), in combined
treatment approaches (4), or even as an alternative to surgery
(5–7), with repeat therapy sessions well-tolerated in the case of
hepatic recurrence (8).
The crucial factor for successful ablative treatment is complete
tumor ablation with an adequate safety margin (9), while
avoiding injury to critical intrahepatic and perihepatic structures.
This is highly dependent on the precision with which the
ablation probes are guided toward and positioned within the
target lesions to subsequently generate adequate ablation zones.
Safe percutaneous targeting is often precluded when using
conventional ultrasonography (US) or computed tomography
(CT) guidance (10), especially for tumors located in challenging
intrahepatic positions such as in the liver dome (11), in a
subcapsular location, or in proximity to the liver hilum or heart
(12). Ablation of such difficult to target tumors results in an
increased risk of complications and associated higher recurrence
rates (13, 14), especially if multiple re-positionings of ablation
probes are necessary to achieve adequate probe positions.
Several techniques have been proposed to target tumors located
in the liver dome, such as artificially induced pneumothorax
(15), pleural effusion (16), or ascites (17), an epicardial fat
pad approach (18), combined imaging techniques (19), or
mathematic models (20), with varying degrees of reliability.
Advanced image-guided navigation technologies aiming to
enhance precision and safety in the targeting of liver tumors
have been introduced (21). First clinical reports on stereotactic
percutaneous ablation of liver tumors are available (22–25), as
well as several comparative studies highlighting the accuracy and
efficiency of using navigation technology vs. conventional image
guidance for tumor targeting (26, 27). While little is known
about factors influencing targeting accuracy and therapeutic
efficacy when using such navigation systems for stereotactic
tumor targeting, they likely facilitate accessibility and treatment
of traditionally difficult to target liver tumors (28). Our group
has previously reported the benefits of using stereotactic image-
guided microwave ablation (SMWA) in the treatment of HCC
(29). The aim of the current study was to investigate factors
influencing targeting accuracy and treatment efficacy when using
SMWA for malignant liver tumors in a multivariable model that
includes challenging lesion locations.
MATERIALS AND METHODS
Patient Population
Data from all consecutive patients treated with SMWA for
malignant liver tumors at our institution between January 2015
and December 2017 were prospectively collected and analyzed
retrospectively. The study protocol was approved by the Regional
Ethical Review Board (KEK-Nr 2017-01038). All patients were
discussed at the weekly multidisciplinary tumor board meeting.
SMWA and the use of stereotactic navigation technology
represent the standard approach at our institution for all patients
in whom percutaneous thermal ablation for malignant liver
tumors is indicated. Thermal ablation therapy was indicated
for patients with (i) unresectable disease due to comorbidities
or lesion location, but in whom local ablation was considered
a potentially curative treatment due to adequate response
to chemotherapy or stable disease, (ii) HCC awaiting liver
transplantation as part of a bridge to transplant or down-staging
approach, (iii) resectable CRLM as part of a prospective multi-
center trial investigating ablation as an alternative to resection
(30), or (iv) multiple liver lesions as part of a multimodal
treatment approach of combined ablation and resection. A
maximum of five lesions were treated in one intervention to
limit overall intervention time and generally lesions up to 5 cm
in diameter were included for SMWA.
Material and Procedural Technique
All interventions were performed in the interventional
radiology CT suite (SOMATOM Definition Flash, Siemens
Healthineers, Erlangen, Germany), by a joint interdisciplinary
team consisting of one of four radiologists and one of four
surgeons. A commercially available navigation system (CAS-
ONE, CAScination AG, Bern, Switzerland) was used to plan
ablation probe trajectories, position ablation probes, and validate
ablation probe positions and ablation zones. The system utilizes
optical tracking of the patient’s abdominal surface via six skin
fiducials that are rigidly co-registered to available image data
(24, 26). Procedures were performed under general anesthesia
with patients positioned on a vacuum mattress, using high-
frequency jet ventilation for respiratory motion control (31).
This quasi-static scenario ensures patient immobility and
minimal displacement of the diaphragm and provides the basis
for accurate and automatic rigid fusion of all performed CT scans
(32). If insufficient fusion quality between scans was suspected
upon visual inspection, a manual point-based registration was
additionally performed. The four main procedural steps are
described and illustrated in Figure 1.
A planning CT scan using a predefined multi-phase imaging
protocol (2 × 64 × 0.6mm; 280-ms gantry rotation time;
pitch factor, 0.6; tube voltage, 100 kV) was performed after
delivery of intravenous contrast medium (Ultravist R© Bayer
Healthcare, Berlin, Germany). The scan window of this first
planning scan included all previously placed skin fiducials. The
planning imaging where the target lesions were best detectable
was transferred to the navigation system. After navigated
ablation probe positioning, a second non-enhanced CT scan
was performed for validation of the correct ablation probe
position. Native scans were repeated for each targeted lesion to
evaluate the respective probe positions before ablation. MWA
(Acculis MTA System, AngioDynamics, Latham, NY, USA) was
performed with energy and time settings adapted to the lesion
diameter. A final contrast-enhanced CT scan with three phases
and intravenous contrast medium was performed for immediate
confirmation of adequate treatment of all target lesions. A
minimal ablation margin of 5–10mm was considered sufficient
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FIGURE 1 | Procedural technique including the four phases of SMWA. (A) Planning phase: Planning of the optimal ablation probe trajectory by selecting the skin entry
point and the intrahepatic target point using the navigation system’s planning module. The target tumor is depicted in red, the planned ablation margin is in orange,
and the simulated ablation zone according to the manufacturer’s prediction is in green. (B) Navigation phase: Navigated alignment of the aiming device along the
planned trajectory, with the cross-hair viewer indicating the trajectory direction. The trajectory depth for consecutive ablation probe positioning is indicated in
millimeters. (C) Ablation probe validation and ablation phase: After insertion of the ablation probe, its positional accuracy relative to the planned trajectory is verified in
the validation scan and calculated in millimeters. If satisfactory, microwave ablation is performed. (D) Ablation zone validation phase: A sufficient ablation zone is
verified by direct overlay of pre- and post-ablation images using the validation module, allowing immediate estimation of the completeness of ablation.
(33, 34). Prophylactic antibiotics were administered routinely. If
safe, all medical staff including anesthesia left the IR suite during
CT scanning.
Assessment of Accuracy and
Procedural Efficiency
The navigation system software allows recording and calculation
of the exact targeting accuracies, trajectory-specific parameters,
and duration of individual procedural steps, data that were
extracted from the navigation system’s log file data. Angles of
the ablation probe trajectories were calculated as indicated in
Figure 2A. Targeting accuracy was assessed as the targeting errors
resulting after ablation probe positioning, defined as the deviance
between the planned trajectory and the achieved ablation probe
position, and was calculated as shown in Figure 2B. Targeting
accuracies were reported as sub-millimetric values resulting from
statistical computation, as visual assessment was limited by
the image resolution of the CT imaging. A large lateral error
implied the repositioning of the ablation probe, defined as the full
retraction of the ablation probe, repeat navigated alignment of the
aiming device and probe re-insertion. Contrarily, longitudinal
errors were easily corrected by advancement or retraction of the
probe along the same trajectory line. For this reason, the lateral
targeting error was defined as the primary target positioning
error (TPE) (27). The navigation system software allows for
the precise planning of multiple ablation probes in excentric
positions as opposed to a single probe in the tumor center,
enabling the generation of larger ablation zones. This positioning
of multiple parallel ablation probes was defined as planned
overlapping ablation and was mostly applied for lesions >3 cm.
Durations of the overall procedure and of individual
procedural steps were recorded. When multiple ablation probes
were positioned per intervention, the durations were calculated
for each probe and added to obtain the total time per
phase per intervention. Clinical complications within 90 days
were assessed and graded according to the Clavien-Dindo
classification (35). Radiological complications without clinical
symptoms as diagnosed on the first post-ablation scan or on
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FIGURE 2 | Schematic illustration of the assessment of ablation probe trajectory angles (A) and of targeting errors of the positioned ablation probes (B). (A) Alpha
angle α: angulation along transverse plane. Beta angle β: angulation along sagittal plane. (B) Theta θ: Angular error. dLat: Lateral error = target positioning error (TPE).
dLong: Longitudinal error.
imaging within the same hospitalization were recorded. Length
of hospital stay was calculated from the day of SMWA to the day
of discharge.
Assessment of Treatment Efficacy
All imaging results were reviewed and interpreted by an
independent radiologist specialized in liver imaging. Immediate
re-ablation was defined as the repeat ablation of one lesion, due
to incomplete tumor coverage after ablation zone validation, at
the end of the same treatment session. Technical success was
reported according to the standardized criteria suggested by
Ahmed et al. (36) and defined as complete tumor coverage by the
ablation zone as assessed on the final CT scan with intravenous
contrast on the day of intervention, including immediate re-
ablations. The first follow-up imaging (MRI or CT) was carried
out at 1–3 months, with re-imaging every 2–4 months thereafter
in patients with stable disease. Early ablation site recurrence
(ASR) was defined as the presence of morphologically detectable
tumor tissue within 10mm from the edge of the ablation zone,
on any of the follow-up imaging performed within 6 months
(including the first follow-up imaging), in lesions with initial
complete tumor coverage. Subgroup analyses were performed for
lesions located in challenging locations, defined as the superior
dorsal liver segments VII/VIII, segment I and a subphrenic
location (<10mm from the diaphragm). The appearance of new
intrahepatic lesions on follow-up imaging was documented.
Statistical Analysis
Continuous data were reported as median, interquartile range
(IQR), and standard deviation (SD), and categorical data were
reported as number and percentage. Regression analysis was
performed to identify factors potentially influencing targeting
accuracy and early ASR per targeted lesion. As multiple lesions
were ablated in the same individual patients and we focused
on per-lesion outcomes, we included repeated measure analyses
in our model. Generalized estimating equations (GEE) using
an exchangeable correlation structure and a robust estimator
of covariance were applied. The resulting regression coefficients
and odds ratios (OR) are comparable to coefficients and OR
resulting from classic regression models, with the benefit of
accounting for intra-class correlations. All factors thought to
potentially influence the precision with which ablation probes
were positioned along the planned trajectory were analyzed
using univariable and multivariable linear GEE, with all co-
variates included in the multivariable model. For lesions with
multiple ablation probe insertions (immediate re-ablations or
planned parallel insertions) per ablated lesion, average values
were used for continuous variables (targeting errors, trajectory
lengths and angles). Results of all tested variables were reported
as regression coefficients with 95% Wald confidence intervals
(CIs). All available factors thought to potentially influence early
ASR were analyzed using univariable and multivariable binary
logistic GEE, with results reported as OR and 95% Wald CI.
The threshold for statistical significance was set to the level α =
0.05. SPSS Statistics (Version 24.0.0, SPSS Inc.) was used for all
statistical analyses.
RESULTS
In 3 years, a total of 301 lesions were treated with SMWA
in 191 interventions in 153 patients. Lesion characteristics and
ablation parameters per lesion are described in Table 1. The
number of ablated tumors per intervention ranged from 1 to
5 and maximum lesion size ranged from 4 to 60mm. Of the
301 treated lesions, 54 (18%) were local recurrences after prior
treatment of the same lesion, including previous thermal ablation
(n = 33), trans-arterial (chemo-)embolization (n = 10), or
resection (n = 11). For 25 lesions (8%), multiple parallel needles
were placed to create larger ablation zones. Correction of probe
positions with probe repositioning was necessary in 4 out of
301 lesions (1%). Two example cases of SMWA for lesions
in challenging intrahepatic locations in liver segment VII and
segment I are illustrated in Figures 3, 4, respectively.
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TABLE 1 | Lesion and ablation characteristics per ablated lesion (n = 301).
Lesion entity
Hepatocellular carcinoma 174 (58)
Colorectal liver metastases 87 (29)
Neuroendocrine metastases 17 (6)
Others 23 (8)
Lesion size
Diameter [mm]a 15 (11–21)
Tumor size >30mm 29 (10)
Lesion location
Segments II–IV 100 (33)
Segments V/VI 59 (20)
Segments VII/VIII 136 (45)
Segment I 6 (2)
Subcapsular locationb 175 (59)
Subphrenic locationb 71 (24)
Vessel proximityc 103 (34)
IVC 7 (2)
Organ proximityb 23 (8)
Gallbladder 5 (2)
Other (colon/stomach/kidney/heart) 18 (6)
Ablation parameters per lesion









Planned overlapping ablations 25 (8)
Number of parallel ablation probes 2 (2–3)
Immediate re-ablations 48 (16)
Ablation probe repositionings 4 (1)
Categorical data are shown as number and percentage, and numerical data are shown as
median and interquartile range. aMaximal diameter measured in a transverse plane. bEdge
of the tumor located within 10mm of the respective structure. cEdge of the tumor located
within 5mm to an intrahepatic artery, vein, or portal vein of a minimum diameter of 3mm.
dAddition of all ablation times per lesions treated in one session (including re-ablations
and planned overlapping ablations).
Targeting Accuracy
Median TPE per positioned ablation probe (n= 384) was 2.9mm
(IQR 1.7–4.5mm, SD 2.3mm). When the ablation probes were
positioned in lesions located in segments VII or VIII (n =
178), segment I (n = 6), or in a subphrenic location (n = 71),
median TPE was 3.5mm (SD 2.3mm), 3.1mm (SD 1.8mm),
and 4.0mm (SD 2.4mm), respectively. All targeting errors and
trajectory-specific parameters per positioned ablation probe are
summarized in Table 2.
Univariable and multivariable analyses of factors influencing
TPE are shown inTable 3. In themultivariablemodel, underlying
liver cirrhosis (linear regression coefficient R 0.668, CI 0.218–
1.119) and targeting trajectory length (R 0.205, CI 0.118–0.291)
had a statistically significant influence on TPE. This implies
a mean increase in TPE of 0.7mm for lesions targeted in
a cirrhotic vs. a non-cirrhotic liver, and of 0.2mm for each
additional centimeter of targeting trajectory length. Contrarily,
challenging intrahepatic lesion locations such as a subphrenic,
superior dorsal, or segment I lesion location, an intercostal
targeting trajectory or varying targeting trajectory angles did not
significantly influence TPE (Table 3).
Procedural Efficiency and Safety
Procedural efficiency and safety are summarized in Table 4.
Median overall duration of SMWA from first to last CT scan was
64min (IQR 46–82min, SD 33 min).
In the 191 SMWA interventions, a total of 10 (5%)
clinical complications occurred. These included six grade I–
II complications, of which were one fever of unknown origin,
one skin infection at the ablation probe entry site, one case
of ascites, one case of transient brachial plexus paralysis due
to arm positioning in a cachectic patient, and two cases of
severe lower thoracic/upper abdominal pain due to pleuritis
and a small perihepatic hematoma, respectively. Three grade
IIIa complications included one pneumothorax and one pleural
effusion, both requiring chest drainage, and one case of
intrahepatic abscess, which was drained percutaneously. A
second case of a suspected intrahepatic abscess with fever
underwent surgical resection of segments VI and VII (grade IIIb
complication); however, histologic analyses did not confirm the
presence of intrahepatic infection. Median length of hospital stay
was 1 day (range, 0–13).
Treatment Efficacy
Immediate re-ablations due to insufficient tumor coverage after
ablation zone validation were performed in 48 (16%) lesions.
The rate of complete tumor coverage on the day of intervention
(technical success) was 96% (290/301 lesions). In the remaining
11 lesions, immediate re-ablation was judged to be unsafe, due to
an increased risk of injury to critical structures or an already large
ablation zone with risk of secondary infection. In the subgroup
of lesions located in challenging locations, technical success was
achieved in 97% (155 of 160) of the lesions. In the subgroup of 25
lesions targeted with multiple parallel ablation probes, technical
success was 96% (23 of 24 lesions), with the one remaining
large (41mm) lesion located in proximity to a main portal vein
bifurcation. This lesion was planned for future resection and was
thus knowingly insufficiently ablated.
Overall ASR within 6 months, including the first follow-
up imaging, was 22% (49 out of 227 previously completely
ablated lesions with available 6 months follow-up), of which
17 (35%) lesions were successfully re-ablated. Twenty-one of
the 49 lesions with ASR (43%) occurred in the setting of
simultaneous appearance of new intrahepatic lesions. In the
subgroups of lesions located in segment VII or VIII, segment
I, or in a subphrenic location, ASR was 16, 23, and 20%,
respectively. In the subgroup of lesions that had undergone
immediate re-ablation, ASR was 18%. Results from the regression
analyses of factors influencing early ASR are summarized in
Table 5. In the univariable analysis of factors influencing early
ASR, colorectal liver metastases and a tumor size >30mm
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FIGURE 3 | Example case of a patient with hepatocellular carcinoma, treated for two adjacent tumors located in segment VII. (A) Planning of targeting trajectories for
three parallel ablation probes to create overlapping ablation zones (green) around the target tumors (red). (B) Top: positioned ablation probe in an immediate
subphrenic position. Bottom: Validation of ablation probe position. (C) Complete ablation of both tumors (red) with a sufficient surrounding ablation margin.
FIGURE 4 | Example case of a patient with a colorectal cancer metastasis (red) located in segment I. (A) Planning of targeting trajectory. (B) Top: targeting trajectory
and tumor in a three-dimensional view. Bottom: Validation of ablation probe position. (C) Complete tumor (red) coverage by the ablation zone with a sufficient ablation
margin; the adjacent main portal vein branches remain patent.
were statistically significant. In the multivariable model, factors
with a significant influence on early ASR were lesion size
(>30mm) and targeting accuracy (TPE >5mm). Challenging
intrahepatic lesion locations or the proximity to intrahepatic
vascular structures or adjacent organs were not predictive factors
of early ASR (Table 5).
DISCUSSION
This study shows that using SMWA for targeting of malignant
liver tumors allows precise, efficient, and effective local tumor
treatment, without compromise in accuracy or efficacy when
targeting lesions located in challenging locations. To our
knowledge, this is the first series analyzing factors influencing
targeting accuracy and treatment efficacy of stereotactic MWA
of malignant liver tumors using a multivariable model to date.
The present work confirms a high overall precision in the
positioning of ablation probes when using SMWA, comparable
to previously reported TPE values after navigated ablation
probe positioning, ranging between 2.9 and 4.0mm (24, 26).
Targeting errors might have been minimally influenced by
TABLE 2 | Targeting accuracy and trajectory-specific parameters, per ablation
probe (n = 384).
Targeting trajectory characteristics
Trajectory length [cm] 11.1 (8.3–13.2)
Intercostal trajectory (n, %) 253 (85)
Trajectory angle α [◦] −15 (−46–6)
Trajectory angle β [◦] 19 (4–32)
Targeting errors
Lateral targeting error, TPE [mm] 2.9 (1.7–4.5)
Longitudinal targeting error [mm]a 1.3 (0.4–2.7)
Angular targeting error [◦] 1.8 (1.1–2.7)
Categorical data are shown as number and percentage, and numerical data are shown
as median and interquartile range. TPE, target positioning error. aTargeting errors prior to
correction of ablation probe position (advancement/retraction) before thermal ablation.
otherwise non-quantifiable fusion errors between scans, despite
optimizing conditions for minimal patient and organ movement
during the procedure. Importantly, a superior dorsal (segment
VII or VIII), segment I or a subphrenic location did not
significantly influence targeting accuracy, confirming the safe
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TABLE 3 | Linear Generalized Estimating Equations (GEE) analysis of factors influencing target positioning errors, per ablated lesion.
Univariable analysis Multivariable analysis
B (95% CI) p-value B (95% CI) p-value
Clinical parameters
Cirrhosis [y/n] 0.791 (0.274, 1.308) 0.003 0.668 (0.218, 1.119) 0.004
Location-specific parameters
Segments I/VII/VIII [y/n] 0.870 (0.363, 1.377) <0.001 0.128 (−0.413, 0.670) 0.642
Subphrenic locationa [y/n] 0.935 (0.293, 1.578) 0.004 0.238 (−0.382, 0.859) 0.415
Subcapsular locationa [y/n] 0.425 (−0.052, 0.902) 0.081 0.371 (−0.080, 0.821) 0.107
Trajectory-specific parameters
Trajectory length [per cm] 0.244 (0.166, 0.323) <0.001 0.205 (0.118, 0.291) <0.001
Intercostal trajectory [y/n] 1.005 (0.549, 1.461) <0.001 0.497 (−0.002, 0.997) 0.051
Trajectory angle αb [per 10◦] −0.025 (−0.126, 0.077) 0.634 −0.088 (−0.184, 0.009) 0.076
Trajectory angle βb [per 10◦] 0.286 (0.073, 0.499) 0.008 0.092 (−0.096, 0.280) 0.336
aEdge of the tumor located within 10mmof the respective structure. bCalculated per 10◦ positive deviation from transverse/sagittal plane. B, regression coefficient; CI, confidence interval.
TABLE 4 | Procedural efficiency and safety, per intervention (n = 191).
Intervention times
Overall procedure time [min]a 64 (46–82)
Trajectory planning [min](A) 11 (7–19)
Navigated probe positioning [min](B) 7 (4–13)
Validation ablation probe [min](C) 8 (4–17)
Validation ablation zone [min](D) 4 (2–6)
Radiological parameters




Grade I–II 6 (3)
Grade IIIa/b 4 (2)
Categorical data are shown as number and percentage, and numerical data are shown
as median and interquartile range. aTime from the first to the last CT scan. (A)Loading of
the first CT scan onto the navigation system until the first switch to the navigation module.
(B)First switch to the navigation module until the last screen shot taken of the positioned
ablation probe. (C)First switch to the validation module until the last log file activity before
loading the next CT scan. (D)First log file activity after the last validation scan until detection
of the last log file activity before the end of the procedure. DLP, dose length product.
accessibility of lesions in challenging intrahepatic locations
when using SMWA. Also, more complex targeting trajectories
such as intercostal trajectories and steep trajectory angles had
no significant influence on targeting accuracy in multivariable
analysis. Since the proposed navigation technique requires
optimal fusion between planning and validation scans to ensure
precise navigational information, factors leading to intracorporal
displacement of the tumor target compromise accuracy of
ablation probe positioning. This explains the significantly higher
TPE when targeting lesions in cirrhotic livers, as the associated
liver stiffness leads to organ distortion when ablation probes are
introduced. The influence of targeting trajectory length on TPE
can be explained by the bending of ablation probe shafts when
applying longer probes, which represents a known challenge
when tracking instruments at their extracorporal end rather than
the tip (37). Hence, when targeting tumors in cirrhotic livers or
when using long targeting trajectories, giving particular attention
to control of the ablation probe position is advocated. An equally
important factor for a safe and efficient treatment is accurate
positioning of the ablation probes at the first targeting attempt
without the need for multiple probe repositioning, which greatly
reduces tissue trauma and complications as well as high radiation
doses (38, 39). The ablation probe repositioning rate in this study
was 1%. Accordingly, patient safety and length of hospital stay
were favorable in this work compared to previous studies on
MWA of liver tumors (6, 22, 40), with low radiation exposure
for patients and no exposure for medical staff.
A further potential benefit of SMWA is the augmented
visualization of the completeness of ablation using the ablation
zone validation module. The precise overlay of pre- and post-
ablation images allows an enhanced visual and 3D interpretation
of the tumor coverage by the ablation zone, with the possibility of
re-ablation in the same treatment session if necessary. Immediate
re-ablation was performed in 48 lesions leading to an overall
technical success rate of 96%, which was knowingly not 100%
due to safety concerns in the remaining 11 lesions. Comparable
technical success rates were shown for lesions in challenging
intrahepatic locations, corresponding to previously reported
success rates after MWA of tumors in the hepatic dome of
between 73 and 94% (20, 41). Due to the possibility of navigated
positioning ofmultiple parallel probes, the same technical success
rate was also shown when targeting larger lesions. The ASR
rate of 22% in this series lies within the wide range of ASRs
of 2–34% reported after MWA of liver tumors (42–44), but
was higher than rates reported in other studies (22). This
is probably influenced by the definition of ASR (detectable
tumor seen on any follow-up imaging after the day of ablation)
likely resulting in more lesions being assessed as ASR in our
study, which in others might be defined as residual unablated
tumor and therefore included in the terms of “primary or
secondary technique efficacy”(36). The latter definitions allow
a wide range of variability in reported efficacy rates and thus
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TABLE 5 | Binary logistic Generalized Estimating Equations (GEE) analysis of factors influencing ablation site recurrence per ablated lesion.
Univariable analysis Multivariable analysis
OR (95% CI) p-value OR (95% CI) p-value
Lesion-specific parameters
HCC [y/n] 0.622 (0.320, 1.208) 0.161 1.038 (0.322, 3.341) 0.950
CRLM [y/n] 2.224 (1.084, 4.564) 0.029 2.280 (0.650, 7.995) 0.198
Tumor size > 30mm [y/n] 3.970 (1.962, 8.033) <0.001 5.221 (2.435, 11.192) <0.001
Location-specific parameters
Segments I/VII/VIII [y/n] 1.226 (0.606, 2.481) 0.571 1.339 (0.578, 3.104) 0.496
Subphrenic locationa [y/n] 0.996 (0.453, 2.190) 0.991 0.564 (0.189, 1.679) 0.303
Subcapsular locationa [y/n] 1.436 (0.700, 2.944) 0.324 1.532 (0.638, 3.680) 0.340
Vessel proximityb [y/n] 1.250 (0.588, 2.656) 0.562 1.053 (0.484, 2.291) 0.896
Organ proximitya [y/n] 0.773 (0.214, 2.790) 0.694 0.607 (0.120, 3.068) 0.545
Procedural parameters
TPE > 5mm [y/n]c 1.874 (0.879, 3.994) 0.104 2.480 (1.064, 5.784) 0.035
aEdge of the tumor located within 10mm of the respective structure. bEdge of the tumor located within 5mm to an intrahepatic artery, vein, or portal vein of a minimum diameter of
3mm. c n = 55 lesions. OR, odds ratio; CI, confidence interval; HCC, hepatocellular carcinoma; CRLM, colorectal liver metastases; TPE, target positioning error.
make comparability of efficacy results difficult. Furthermore, we
included all patients consecutively treated with MWA for any
malignant liver tumors at our tertiary referral center, resulting
in an unfiltered group of lesions of multiple sizes, locations, and
disease stages. While not analyzed in our model, an aggressive
tumor biology and/or advanced disease stage of treated patients
can be assumed, since 43% of all lesions with ASR occurred in
patients with diffuse intrahepatic disease progression within 6
months. The short follow-up period of 6 months was chosen
for a per-lesion analysis of factors influencing early ASR. The
high rates of intrahepatic recurrences after initial treatments for
CRLM and HCC (70–80%) (7, 45) often imply the need for
multiple repeat liver-targeted treatments. Therefore, describing
ASRs per lesion after long follow-up periods is of limited clinical
value and cancer-specific time-to-progression analyses will be
more adequate.
To further improve the assessment of complete ablation and
technical success, safety margins will be integrated into the
immediate ablation zone validation module of the navigation
system. We are currently investigating the quantification of
tumor coverage by the ablation zone by computed volume
segmentation, which will enable refined analyses of liver- and
tumor-related factors associated with the expansion of ablation
zones (46). This will also allow a true distinction between
local recurrence and residual unablated tumor, enabling refined
analyses on factors influencing true local tumor recurrence (47).
Odisio et al. reported local tumor progression rates of 18% after
MWA of CRLM, which were not influenced by a subcapsular
lesion location in regression analysis (48). In the present work,
early ASR was not affected by a challenging lesion location or
subcapsular position; however, a TPE > 5mm was shown to be
an independent predictor of early local tumor control.
A potential limitation of the present study is that the
regression model for treatment efficacy focused on location-
specific parameters and targeting accuracy, excluding other
factors that could also have a potential impact on treatment
efficacy. These would primarily be parameters specific to different
cancer types, which are difficult to include in the current analysis
that involves varying tumor entities. The results presented in this
work allow a first estimation regarding a possible enhancement
of targeting accuracy and tumor accessibility when using SMWA,
especially for lesions in challenging intrahepatic locations. A true
superiority of using navigation technology over conventional
image guidance for tumor targeting must be confirmed in future
well-designed prospective comparative studies. Ultimately, we
believe that SMWA has its greatest merit when aiming to
efficiently target lesions in challenging intrahepatic locations
requiring more complex targeting trajectories. Using SMWA also
for easier-to-reach liver tumors, as reported in this series, allows
for expertise within the team to increase, so thatmore challenging
lesions can be safely treated. The standardization of the treatment
technique also leads to short learning curves and the generation
of reproducible and comparable results when using such novel
navigation technology.
In conclusion, SMWA allows for accurate targeting and
effective treatment of malignant liver tumors, even for
lesions in challenging locations, with targeting accuracy
independently predicting efficacy in our model. Allowing for
many tumors to be safely reached, SMWA might broaden
treatment eligibility for patients with otherwise difficult to
target tumors.
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